Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy
This study has been withdrawn prior to recruitment.
Study NCT00003514 Information provided by National Cancer Institute (NCI)
First Received: November 1, 1999 Last Updated: December 4, 2006
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Merkel Cell Carcinoma
Islet Cell Carcinoma
Neuroendocrine Carcinoma
Pituitary Tumor
Additional conditions recognized in this trial
Carcinoma
Carcinoma, Islet Cell
Carcinoma, Merkel Cell
Carcinoma, Neuroendocrine
Neuroendocrine Tumors
Pituitary Neoplasms
More general conditions related to this trial
Adenocarcinoma
Brain Diseases
Brain Neoplasms
Central Nervous System Diseases
Central Nervous System Neoplasms
Digestive System Diseases
Digestive System Neoplasms
Endocrine Gland Neoplasms
Endocrine System Diseases
Hypothalamic Diseases
Hypothalamic Neoplasms
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Nervous System Diseases
Nervous System Neoplasms
Neuroectodermal Tumors
Pancreatic Diseases
Pancreatic Neoplasms
Pituitary Diseases
Supratentorial Neoplasms
Interventions listed in this trial
antineoplaston A10
antineoplaston AS2-1
alternative product therapy
biological therapy
biologically based therapies
cancer prevention intervention
differentiation therapy
Sponsors listed in this trial
Burzynski Research Institute
Back to top of Main Content
